
The maker of the pricey new Alzheimer’s drug Aduhelm (aducanumab) said Monday it will slash the cost of its medication in half, effective Jan. 1, 2022. The move follows widespread criticism of the drug’s original $56,000-a-year price tag. The reduction in the wholesale acquisition cost announced by Biogen means that the annual cost for a… read on > read on >